Overview: Parietal Cell Antibody IFA Dilutions TestIntroduction: The Parietal Cell Antibody IFA Dilutions Test quantifies parietal cell antibodies to diagnose autoimmune gastritis, causing anemia. Following 2023 ACG guidelines, it uses immunoassays for high specificity, supporting autoimmune screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected autoimmune gastritis or pernicious anemia.
Other Names: Parietal Cell IFA Dilutions Assay, Autoimmune Gastritis Titer Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Parietal cell antibody testing began in the 1960s with autoimmune gastritis research. Dilution methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Quantifies parietal cell antibodies to diagnose autoimmune gastritis, guides treatment, and evaluates patients with anemia.
Test Parameters: 1. Parietal Cell Antibody Titer
Pretest Condition: No fasting required. Collect serum or saliva. Report history of anemia or autoimmune symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document anemia, fatigue, or history of autoimmune diseases. Include current medications, especially vitamin B12 supplements.
Consent: Written consent required, detailing the tests purpose, autoimmune gastritis implications, and risks of sample collection.
Procedural Considerations: Uses immunofluorescence assay (IFA) with dilutions to quantify parietal cell antibody titers. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for autoimmune gastritis diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: High antibody titers confirm autoimmune gastritis, guiding vitamin B12 therapy. Negative or low titers may require intrinsic factor testing.
Specialist Consultation: Consult a gastroenterologist for result interpretation and treatment planning.
Additional Supporting Tests: Intrinsic factor antibody, vitamin B12 levels, or gastric biopsy to confirm autoimmune gastritis diagnosis.
Test Limitations: Non-specific for certain autoimmune conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: ACG Gastritis Guidelines, 2023; American Journal of Gastroenterology, Laine L, 2022.
